- Simplified reporting of ICSRs and re-routing of ICSRs to Member States, as MAHs will no longer have to provide these reports to NCAs, but directly to EudraVigilance;
- Better detection of new or changing safety issues;
- Increased transparency based on broader access to reports of suspected adverse reactions via the adrreports.eu portal.
- Enhanced search and more efficient data analysis capabilities;
- Increased system capacity and performance to support large volumes of users and reports;
- More efficient collaboration with the World Health Organisation, as EMA will make the reports of individual cases of suspected adverse reactions within EEA available to WHO Uppsala Monitoring Centre Directly from Eudravigilance (Member States will not have to do this task anymore).
- EVWEB release notes – new
- EVWEB User Manual (updated)
- EVDAS release notes for MAHs – new (published on the EVDAS welcome page)
- EVDAS user manual for MAHs – new
- XCOMP release notes (updated)
- EudraVigilance